Human GRAIL/RNF128 Antibody

Detection of Human GRAIL/RNF128 by Western Blot.

Western blot shows lysates of MCF-7 human breast cancer cell line. PVDF Membrane was probed with 1 µg/mL of Human GRAIL/RNF128 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6234) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for GRAIL/RNF128 at approximately 45 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.

Detection of Human GRAIL/RNF128 by Western Blot

GRAIL1 downregulates, but GRAIL2 upregulates, CD3 isoforms.(A) In HeLa cells we overexpressed GFP-tagged CD3-delta and zeta in the presence and absence of either DDK-tagged GRAIL1 or V5-tagged GRAIL2. Cell lysates were prepared 24 hours after transfection and subjected to immunoblotting as indicated. (B–E) DDK-tagged CD3 isoforms ( epsilon, gamma, delta, zeta ) were co-overexpressed in the presence of V5-tagged GRAIL1, GRAIL2, or both isoforms. Cell lysates were then subjected to immunoblotting. (F and G) Patient PBMCs were flow-sorted to isolate T cells, which were then exposed to alpha CD3/CD28 antibodies for 10 days. Cells were FACS-sorted based on CD3 and BTLA expression and subjected to either quantitative reverse transcriptase PCR or immunoblotting. ddC, ∆∆Ct. (H) Human T cell leukemia (Jurkat) cells were subjected to transfection using either control or 2 independent GRAIL1-specific siRNAs. Forty-eight hours after transfection, cell lysates were prepared and subjected to immunoblotting using indicated antibodies. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38781019), licensed under a CC-BY license. Not internally tested by R&D Systems.